CD69 is the crucial regulator of intestinal inflammation: A new target molecule for IBD treatment?

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Radulovic, Katarina ^a,b   Niess, Jan Hendrik ^c  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD69 ANTIGEN; CORTICOSTEROID; GAMMA INTERFERON INDUCIBLE PROTEIN 10 ANTIBODY; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

CD69 GENE; DRUG TARGETING; GENE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE MUCOSA; LEUKOCYTE; LYMPHOCYTE MIGRATION; MEMORY T LYMPHOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; CHEMISTRY; CYTOLOGY; ENTERITIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOMARKERS; CELL DIFFERENTIATION; CELL MOVEMENT; ENTERITIS; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84924565324     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/497056     Document Type: Review

References (270)

1. F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, "Host-bacterial mutualism in the human intestine," Science, vol. 307, no. 5717, pp. 1915-1920, 2005.
2. J. Qin, R. Li, J. Raes et al., "A human gut microbial gene catalogue established by metagenomic sequencing," Nature, vol. 464, no. 7285, pp. 59-65, 2010.
3. C. Nagler-Anderson, "Man the barrier! strategic defences in the intestinal mucosa," Nature Reviews Immunology, vol. 1, no. 1, pp. 59-67, 2001.
4. M. A. McGuckin, S. K. Lindén, P. Sutton, and T. H. Florin, "Mucin dynamics and enteric pathogens," Nature Reviews Microbiology, vol. 9, no. 4, pp. 265-278, 2011.
5. + dendritic cells in the small intestine," Nature, vol. 483, no. 7389, pp. 345-349, 2012.
6. M. A. Kinnebrew and E. G. Pamer, "Innate immune signaling in defense against intestinal microbes," Immunological Reviews, vol. 245, no. 1, pp. 113-131, 2012.
7. N. Miron and V. Cristea, "Enterocytes: active cells in tolerance to food and microbial antigens in the gut," Clinical and Experimental Immunology, vol. 167, no. 3, pp. 405-412, 2012.
8. M. Shan, M. Gentile, J. R. Yeiser et al., "Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals," Science, vol. 342, no. 6157, pp. 447-453, 2013.
9. H. Cheroutre, F. Lambolez, and D. Mucida, "The light and dark sides of intestinal intraepithelial lymphocytes," Nature Reviews Immunology, vol. 11, no. 7, pp. 445-456, 2011.
10. A. M. Mowat, "Anatomical basis of tolerance and immunity to intestinal antigens," Nature Reviews Immunology, vol. 3, no. 4, pp. 331-341, 2003.
11. F. van Wijk and H. Cheroutre, "Mucosal T cell singut homeostasis and inflammation," Expert Review of Clinical Immunology, vol. 6, no. 4, pp. 559-566, 2010.
12. + regulatory T cells in the lamina propria," Immunity, vol. 34, no. 2, pp. 237-246, 2011.
13. M. F. du Pré and J. N. Samsom, "Adaptive T-cell responses regulating oral tolerance to protein antigen," Allergy, vol. 66, no. 4, pp. 478-490, 2011.
14. A. Izcue, J. L. Coombes, and F. Powrie, "Regulatory lymphocytes and intestinal inflammation," Annual Review of Immunology, vol. 27, pp. 313-338, 2009.
15. F. Geissmann, M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley, "Development of monocytes, macrophages, and dendritic cells," Science, vol. 327, no. 5966, pp. 656-661, 2010.
16. R. de Maria, S. Fais, M. Silvestri et al., "Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes," European Journal of Immunology, vol. 23, no. 12, pp. 3104-3108, 1993.
17. R. Testi, D. D'Ambrosio, R. de Maria, and A. Santoni, "The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells," Immunology Today, vol. 15, no. 10, pp. 479-483, 1994.
18. A. S. Llera, F. Viedma, F. Sánchez-Madrid, and J. Tormo, "Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69," Journal of Biological Chemistry, vol. 276, no. 10, pp. 7312-7319, 2001.
19. S. F. Ziegler, S. D. Levin, L. Johnson et al., "The mouse CD69 gene: structure, expression, and mapping to the NK gene complex," Journal of Immunology, vol. 152, no. 3, pp. 1228-1236, 1994.
20. J. Hamann, H. Fiebig, and M. Strauss, "Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain," Journal of Immunology, vol. 150, no. 11, pp. 4920-4927, 1993.
21. E. Alari-Pahissa, L. Notario, E. Lorente et al., "CD69 does not affect the extent of T cell priming," PLoS ONE, vol. 7, no. 10, Article ID e48593, 2012.
22. R. González-Amaro, J. R. Cortés, F. Sánchez-Madrid, and P. Martín, "Is CD69 an effective brake to control inflammatory diseases?" Trends in Molecular Medicine, vol. 19, no. 10, pp. 625-632, 2013.
23. L. Li, D. Qiao, X. Fu, S. Lao, X. Zhang, and C. Wu, "Identification of M. tuberculosis-specific th1 cells expressing CD69 generated in vivo in pleural fluid cells from patients with tuberculous pleurisy," PLoS ONE, vol. 6, no. 8, Article ID e23700, 2011.
24. N. Mori, C. Ishikawa, and M. Senba, "Induction of CD69 expression by cagPAI-positive Helicobacter pylori infection," World Journal of Gastroenterology, vol. 17, no. 32, pp. 3691-3699, 2011.
25. P. Pignatti, L. Perfetti, E. Galdi et al., "Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge," Allergy, vol. 57, no. 5, pp. 411-416, 2002.
26. D. Sancho, A. G. Santis, J. L. Alonso-Lebrero, F. Viedma, R. Tejedor, and F. Sánchez-Madrid, "Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors," Journal of Immunology, vol. 165, no. 7, pp. 3868-3875, 2000.
27. R. Testi, J. H. Phillips, and L. L. Lanier, "T cell activation via Leu-23 (CD69)," The Journal of Immunology, vol. 143, no. 4, pp. 1123-1128, 1989.
28. M. Cebrian, E. Yague, M. Rincon, M. Lopez-Botet, M. O. de Landazuri, and F. Sanchez-Madrid, "Triggering of T cell proliferation through aim, an activation inducer molecule expressed on activated human lymphocytes," Journal of Experimental Medicine, vol. 168, no. 5, pp. 1621-1637, 1988.
29. A. G. Santis, M. R. Campanero, J. L. Alonso et al., "Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway," European Journal of Immunology, vol. 22, no. 5, pp. 1253-1259, 1992.
30. R. de Maria, M. G. Cifone, R. Trotta et al., "Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors," Journal of Experimental Medicine, vol. 180, no. 5, pp. 1999-2004, 1994.
31. I. B. Mcinnes, B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew, "Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis," Nature Medicine, vol. 3, no. 2, pp. 189-195, 1997.
32. P. Lauzurica, D. Sancho, M. Torres et al., "Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice," Blood, vol. 95, no. 7, pp. 2312-2320, 2000.
33. P. Martín, M. Gómez, A. Lamana et al., "The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity," Journal of Allergy and Clinical Immunology, vol. 126, no. 2, pp. 355-365.e3, 2010.
34. T. Miki-Hosokawa, A. Hasegawa, C. Iwamura et al., "CD69 controls the pathogenesis of allergic airway inflammation," Journal of Immunology, vol. 183, no. 12, pp. 8203-8215, 2009.
35. K. Murata, M. Inami, A. Hasegawa et al., "CD69-null mice protected from arthritis induced with anti-type II collagen antibodies," International Immunology, vol. 15, no. 8, pp. 987-992, 2003.
36. D. Sancho, M. Gómez, F. Viedma et al., "CD69 downregulates autoimmune reactivity through active transforming growth factor-α production in collagen-induced arthritis," The Journal of Clinical Investigation, vol. 112, no. 6, pp. 872-882, 2003.
37. A. Lamana, D. Sancho, A. Cruz-Adalia et al., "The role of CD69 in acute neutrophil-mediated inflammation," European Journal of Immunology, vol. 36, no. 10, pp. 2632-2638, 2006.
38. A. Cruz-Adalia, L. J. Jiménez-Borreguero, M. Ramírez-Huesca et al., "CD69 limits the severity of cardiomyopathy after autoimmune myocarditis," Circulation, vol. 122, no. 14, pp. 1396-1404, 2010.
39. J. Vega-Ramos, E. Alari-Pahissa, J. D. Valle et al., "CD69 limits early inflammatory diseases associated with immune response to Listeria monocytogenes infection," Immunology and Cell Biology, vol. 88, no. 7, pp. 707-715, 2010.
40. E. Esplugues, D. Sancho, J. Vega-Ramos et al., "Enhanced antitumor immunity in mice deficient in CD69," Journal of Experimental Medicine, vol. 197, no. 9, pp. 1093-1106, 2003.
41. E. Esplugues, J. Vega-Ramos, D. Cartoixa et al., "Induction of tumor NK-cell immunity by anti-CD69 antibody therapy," Blood, vol. 105, no. 11, pp. 4399-4406, 2005.
42. K. Radulovic, C. Manta, V. Rossini et al., "CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential," Journal of Immunology, vol. 188, no. 4, pp. 2001-2013, 2012.
43. K. Radulovic, V. Rossini, C. Manta, K. Holzmann, H. A. Kestler, and J. H. Niess, "The early activation marker CD69 regulates the expression of chemokines and CD4 T cell accumulation in intestine," PLoS ONE, vol. 8, no. 6, Article ID e65413, 2013.
44. A. Hasegawa, C. Iwamura, M. Kitajima et al., "Crucial role for CD69 in the pathogenesis of dextran sulphate sodium-induced colitis," PLoS ONE, vol. 8, no. 6, Article ID e65494, 2013.
45. A. G. Santis, M. López-Cabrera, J. Hamann, M. Strauss, and F. Sánchez-Madrid, "Structure of the gene coding for the human early lymphocyte activation antigen CD69: a C-type lectin receptor evolutionarily related with the gene families of natural killer cell-specific receptors," European Journal of Immunology, vol. 24, no. 7, pp. 1692-1697, 1994.
46. J. M. Bjorndahl, S. Nakamura, T. Hara, L. K. L. Jung, and S. Man Fu, "The 28-kDa/32-kDa activation antigen EA 1. Further characterization and signal requirements for its expression," Journal of Immunology, vol. 141, no. 12, pp. 4094-4100, 1988.
47. F. Gerosa, M. Tommasi, M. Scardoni et al., "Structural analysis of the CD69 early activation directed to different epitopes," Molecular Immunology, vol. 28, no. 1-2, pp. 159-168, 1991.
48. K. Radulovic, The role of CD69 molecule in the mucosal immune system of the intestine [Ph.D. thesis], University of Ulm, 2012, http://vts.uni-ulm.de/docs/2012/8076/vts807611760.pdf.
49. P. Kolenko, T. Skálová, O. Vanek et al., "The high-resolution structure of the extracellular domain of human CD69 using a novel polymer," Acta Crystallographica Section F, vol. 65, pp. 1258-1260, 2009.
50. K. Drickamer, "C-type lectin-like domains," Current Opinion in Structural Biology, vol. 9, no. 5, pp. 585-590, 1999.
51. 2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E," Journal of Biological Chemistry, vol. 288, no. 30, pp. 21667-21677, 2013.
52. A. Cerutti, L. Trentin, R. Zambello et al., "The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity," Journal of Immunology, vol. 157, no. 5, pp. 1854-1862, 1996.
53. R. A. Childs, C. Galustian, A. M. Lawson et al., "Recombinant soluble human CD69 dimer produced in Escherichia coli: reevaluation of saccharide binding," Biochemical and Biophysical Research Communications, vol. 266, no. 1, pp. 19-23, 1999.
54. D. S. Aaronson and C. M. Horvath, "A road map for those who don't know JAK-STAT," Science, vol. 296, no. 5573, pp. 1653-1655, 2002.
55. R. Testi, J. H. Phillips, and L. L. Lanier, "Constitutive expression of A phosphorylated activation antigen (Leu 23) by CD3(bright) human thymocytes," Journal of Immunology, vol. 141, no. 8, pp. 2557-2563, 1988.
56. R. Testi, F. Pulcinelli, L. Frati, P. P. Gazzaniga, and A. Santoni, "CD69 is expressed on platelets and mediates platelet activation and aggregation," Journal of Experimental Medicine, vol. 172, no. 3, pp. 701-707, 1990.
57. P. Sanchez-Mateos, M. Cebrian, A. Acevedo, M. Lopez-Botet, M. O. De Landazuri, and F. Sanchez-Madrid, "Expression of a gp33/27, 000MWactivation inducer molecule (AIM)on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies," Immunology, vol. 68, no. 1, pp. 72-79, 1989.
58. A. Risso, D. Smilovich, M. C. Capra et al., "CD69 in resting and activated T lymphocytes: its association with a GTP binding protein and biochemical requirements for its expression," Journal of Immunology, vol. 146, no. 12, pp. 4105-4114, 1991.
59. L. R. Shiow, D. B. Rosen, N. Brdičková et al., "CD69 acts downstream of interferon-α/β to inhibit S1P 1 and lymphocyte egress from lymphoid organs," Nature, vol. 440, no. 7083, pp. 540-544, 2006.
60. E. Kamphuis, T. Junt, Z. Waibler, R. Forster, and U. Kalinke, "Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia," Blood, vol. 108, no. 10, pp. 3253-3261, 2006.
61. M. Reddy, E. Eirikis, C. Davis, H. M. Davis, and U. Prabhakar, "Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function," Journal of Immunological Methods, vol. 293, no. 1-2, pp. 127-142, 2004.
62. R. Testi, J. H. Phillips, and L. L. Lanier, "Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C," Journal of Immunology, vol. 142, no. 6, pp. 1854-1860, 1989.
63. C. Fiocchi, "Future of IBD pathogenesis: how much work is left to do?" Inflammatory Bowel Diseases, vol. 14, supplement 2, pp. S145-S147, 2008.
64. S. P. Jeong, J.-A. Kang, and S.-G. Park, "Intestinal intraepithelial TCRγδ+ T cells are activated by normal commensal bacteria," The Journal of Microbiology, vol. 50, no. 5, pp. 837-841, 2012.
65. S. Mandala, R. Hajdu, J. Bergstrom et al., "Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists," Science, vol. 296, no. 5566, pp. 346-349, 2002.
66. R. Elgueta, F. E. Sepulveda, F. Vilches et al., "Imprinting of CCR9 on CD4 T cells requires IL-4 signaling on mesenteric lymph node dendritic cells," The Journal of Immunology, vol. 180, no. 10, pp. 6501-6507, 2008.
67. S. I. Hammerschmidt, M. Friedrichsen, J. Boelter et al., "Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice," Journal of Clinical Investigation, vol. 121, no. 8, pp. 3051-3061, 2011.
68. J. R. Mora, "Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids," Inflammatory Bowel Diseases, vol. 14, no. 2, pp. 275-289, 2008.
69. V. Brinkmann, "FTY720: mechanism of action and potential benefit in organ transplantation," Yonsei Medical Journal, vol. 45, no. 6, pp. 991-997, 2004.
70. I. L. Grigorova, S. R. Schwab, T. G. Phan et al., "Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells," Nature Immunology, vol. 10, no. 1, pp. 58-65, 2009.
71. A. D. Luster, R. Alon, and U. H. von Andrian, "Immune cell migration in inflammation: present and future therapeutic targets," Nature Immunology, vol. 6, no. 12, pp. 1182-1190, 2005.
72. M. Matloubian, C.G. Lo, G. Cinamonetal., "Lymphocytee gress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1," Nature, vol. 427, no. 6972, pp. 355-360, 2004.
73. C. Feng, K. J. Woodside, B. A. Vance et al., "A potential role for CD69 in thymocyte emigration," International Immunology, vol. 14, no. 6, pp. 535-544, 2002.
74. T. Nakayama, D. J. Kasprowicz, M. Yamashita et al., "The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression," Journal of Immunology, vol. 168, no. 1, pp. 87-94, 2002.
75. O. Schulz, M. Ugur, M. Friedrichsen et al., "Hypertrophy of infected Peyer's patches arises from global, interferonreceptor, and CD69-independent shutdown of lymphocyte egress," Mucosal Immunology, vol. 7, no. 4, pp. 892-904, 2014.
76. + T cells with a distinct phenotype and migratory pattern," The Journal of Immunology, vol. 190, no. 3, pp. 970-976, 2013.
77. G. F. Gerberick, L. W. Cruse, C. M. Miller, E. E. Sikorski, and G. M. Ridder, "Selective modulation of t cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment," Toxicology and Applied Pharmacology, vol. 146, no. 1, pp. 1-10, 1997.
78. R. W. Dutton, L. M. Bradley, and S. L. Swain, "T cell memory," Annual Review of Immunology, vol. 16, pp. 201-223, 1998.
79. F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, "Two subsets of memory T lymphocytes with distinct homing potentials and effector functions," Nature, vol. 401, no. 6754, pp. 708-712, 1999.
80. F. Sallusto, A. Langenkamp, J. Geginat, and A. Lanzavecchia, "Functional subsets of memory T cells identified by CCR7 expression," Current Topics in Microbiology and Immunology, vol. 251, pp. 167-171, 2000.
81. T. Gebhardt and F. R. Carbone, "Immunology: a helpers' guide to infection," Nature, vol. 462, no. 7272, pp. 418-419, 2009.
82. + T cells are resident in normal skin," The Journal of Immunology, vol. 176, no. 7, pp. 4431-4439, 2006.
83. Y.-T. Lee, J. E. Suarez-Ramirez, T. Wu et al., "Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes," Journal of Virology, vol. 85, no. 9, pp. 4085-4094, 2011.
84. D. L. Turner, K. L. Bickham, J. J. Thome et al., "Lung niches for the generation and maintenance of tissue-resident memory T cells," Mucosal Immunology, vol. 7, no. 3, pp. 501-510, 2014.
85. L. M. Wakim, A. Woodward-Davis, and M. J. Bevan, "Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 42, pp. 17872-17879, 2010.
86. K. Tokoyoda, S. Zehentmeier, A. N. Hegazy et al., "Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow," Immunity, vol. 30, no. 5, pp. 721-730, 2009.
87. D. Masopust, V. Vezys, E.J. Wherry, D.L. Barber, and R. Ahmed, "Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population," The Journal of Immunology, vol. 176, no. 4, pp. 2079-2083, 2006.
88. D. Masopust, D. Choo, V. Vezys et al., "Dynamic T cell migration program provides resident memory within intestinal epithelium," Journal of Experimental Medicine, vol. 207, no. 3, pp. 553-564, 2010.
89. K. A. Casey, K. A. Fraser, J. M. Schenkel et al., "Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues," Journal of Immunology, vol. 188, no. 10, pp. 4866-4875, 2012.
90. L. S. Cauley and L. Lefrançois, "Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells," Mucosal Immunology, vol. 6, no. 1, pp. 14-23, 2013.
91. N. Zhang and M. J. Bevan, "Transforming growth factor-β signaling controls the formation and maintenance of gutresident memory T cells by regulating migration and retention," Immunity, vol. 39, no. 4, pp. 687-696, 2013.
92. K. Shinoda, K. Tokoyoda, A. Hanazawa et al., "Type II membrane protein CD69 regulates the formation of resting T-helper memory," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7409-7414, 2012.
93. A. Hanazawa, M. Löhning, A. Radbruch, and K. Tokoyoda, "CD49b/CD69-dependent generation of resting T helper cell memory," Frontiers in Immunology, vol. 4, article 183, 2013.
94. T. Sathaliyawala, M. Kubota, N. Yudanin et al., "Distribution and compartmentalization of human circulating and tissueresident memory T cell subsets," Immunity, vol. 38, no. 1, pp. 187-197, 2013.
95. D. Haribhai, W. Lin, B. Edwards et al., "A central role for induced regulatory T cells in tolerance induction in experimental colitis," Journal of Immunology, vol. 182, no. 6, pp. 3461-3468, 2009.
96. M. Murai, O. Turovskaya, G. Kim et al., "Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis.," Nature immunology, vol. 10, no. 11, pp. 1178-1184, 2009.
97. + regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-γ," Arthritis research & Therapy, vol. 7, no. 2, pp. R402-R415, 2005.
98. W.-P. Zheng and R. A. Flavell, "The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells," Cell, vol. 89, no. 4, pp. 587-596, 1997.
99. E. Martín-Gayo, E. Sierra-Filardi, A. L. Corbí, and M. L. Toribio, "Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development," Blood, vol. 115, no. 26, pp. 5366-5375, 2010.
100. + T regulatory cells," Journal of Immunology, vol. 178, no. 7, pp. 4022-4026, 2007.
101. L. Gorelik and R. A. Flavell, "Transforming growth factor-β in T-cell biology," Nature Reviews Immunology, vol. 2, no. 1, pp. 46-53, 2002.
102. E. M. Shevach, D. Q. Tran, T. S. Davidson, and J. Andersson, "The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T cell function," European Journal of Immunology, vol. 38, no. 4, pp. 915-917, 2008.
103. + regulatory T cells is mediated by cell surface-bound transforming growth factor β," The Journal of Experimental Medicine, vol. 194, no. 5, pp. 629-644, 2001.
104. M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, "Transforming growth factor-β regulation of immune responses," Annual Review of Immunology, vol. 24, pp. 99-146, 2006.
105. M. Marazuela, M. A. García-López, N. Figueroa-Vega et al., "Regulatory T cells in human autoimmune thyroid disease," The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3639-3646, 2006.
106. + T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance," Journal of Immunology, vol. 161, no. 3, pp. 1267-1273, 1998.
107. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1," The Journal of Immunology, vol. 182, no. 1, pp. 111-120, 2009.
108. R. Gandhi, M. F. Farez, Y. Wang, D. Kozoriz, F. J. Quintana, and H. L. Weiner, "Cutting edge: Human latency-associated peptide+ T cells: a novel regulatory T cell subset," Journal of Immunology, vol. 184, no. 9, pp. 4620-4624, 2010.
109. -regulatory T cells involved in disease progression of human hepatocellular carcinoma?" Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1469-1470, 2011.
110. J. Zhu, A. Feng, J. Sun et al., "Increased CD4+CD69+CD25-T cells in patients with hepatocellular carcinoma are associated with tumor progression," Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1519-1526, 2011.
111. D. Sekar, C. Hahn, B. Brüne, E. Roberts, and A. Weigert, "Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity," European Journal of Immunology, vol. 42, no. 6, pp. 1585-1598, 2012.
112. +T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants," Clinical Transplantation, vol. 26, no. 2, pp. E158-E167, 2012.
113. F. Saldanha-Araujo, R. Haddad, K. C. Farias et al., "Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-κB signalling," Journal of Cellular and Molecular Medicine, vol. 16, no. 6, pp. 1232-1244, 2012.
114. + T cell activation, but augments CD69 expression and TGF-beta1-mediated generation of regulatory T cells at late phase," PLoS ONE, vol. 8, no. 4, Article ID e62300, 2013.
115. R. F. Leal, N. Planell, R. Kajekar et al., "Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy," Gut, 2014.
116. M. Z. Cader and A. Kaser, "Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation," Gut, vol. 62, no. 11, pp. 1653-1664, 2013.
117. R. J. Xavier and D. K. Podolsky, "Unravelling the pathogenesis of inflammatory bowel disease," Nature, vol. 448, no. 7152, pp. 427-434, 2007.
118. I. Koboziev, F. Karlsson, and M. B. Grisham, "Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation," Annals of the New York Academy of Sciences, vol. 1207, supplement 1, pp. E86-E93, 2010.
119. D. V. Ostanin, J. Bao, I. Koboziev et al., "T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade," American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 296, no. 2, pp. G135-G146, 2009.
120. C. Abraham and J. H. Cho, "Inflammatory bowel disease," The New England Journal of Medicine, vol. 361, no. 21, pp. 2066-2078, 2009.
121. W. Strober, I. Fuss, and P. Mannon, "The fundamental basis of inflammatory bowel disease," The Journal of Clinical Investigation, vol. 117, no. 3, pp. 514-521, 2007.
122. G. Bouma and W. Strober, "The immunological and genetic basis of inflammatory bowel disease," Nature Reviews Immunology, vol. 3, no. 7, pp. 521-533, 2003.
123. W. S. Garrett, J. I. Gordon, and L. H. Glimcher, "Homeostasis and inflammation in the intestine," Cell, vol. 140, no. 6, pp. 859-870, 2010.
124. A. Kaser, A. H. Lee, A. Franke et al., "XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease," Cell, vol. 134, no. 5, pp. 743-756, 2008.
125. A. Franke, T. Balschun, T. H. Karlsen et al., "Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility," Nature Genetics, vol. 40, no. 11, pp. 1319-1323, 2008.
126. S. Brand, "Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease," Gut, vol. 58, no. 8, pp. 1152-1167, 2009.
127. D. K. Podolsky, "Inflammatory bowel disease," The New England Journal of Medicine, vol. 347, no. 6, pp. 417-429, 2002.
128. L. E. Targownik and C. N. Bernstein, "Infectious and malignant complications of tnf inhibitor therapy in ibd," American Journal of Gastroenterology, vol. 108, no. 12, pp. 1835-1842, 2013.
129. C. P. Tamboli, D. B. Doman, and A. Patel, "Current and future role of biomarkers in Crohn's disease risk assessment and treatment," Clinical and Experimental Gastroenterology, vol. 4, no. 1, pp. 127-140, 2011.
130. H. Ito, M. Takazoe, Y. Fukuda et al., "A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease," Gastroenterology, vol. 126, no. 4, pp. 989-996, 2004.
131. W. J. Sandborn, B. G. Feagan, P. Rutgeerts et al., "Vedolizumab as induction and maintenance therapy for Crohn's disease," The New England Journal of Medicine, vol. 369, no. 8, pp. 711-721, 2013.
132. C. R. Mackay, "Moving targets: cell migration inhibitors as new anti-inflammatory therapies," Nature Immunology, vol. 9, no. 9, pp. 988-998, 2008.
133. M. Eberhardson, P. Marits, M. Jones et al., "Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis," Clinical Immunology, vol. 149, no. 1, pp. 73-82, 2013.
134. M. C. Fantini, A. Rizzo, D. Fina et al., "Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression," Gastroenterology, vol. 136, no. 4, pp. 1308-1316, 2009.
135. T. Hünig, "The storm has cleared: lessons from the CD28 superagonist TGN1412 trial," Nature Reviews Immunology, vol. 12, no. 5, pp. 317-318, 2012.
136. F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, "Host-bacterial mutualism in the human intestine," Science, vol. 307, no. 5717, pp. 1915-1920, 2005.
137. J. Qin, R. Li, J. Raes et al., "A human gut microbial gene catalogue established by metagenomic sequencing," Nature, vol. 464, no. 7285, pp. 59-65, 2010.
138. C. Nagler-Anderson, "Man the barrier! strategic defences in the intestinal mucosa," Nature Reviews Immunology, vol. 1, no. 1, pp. 59-67, 2001.
139. M. A. McGuckin, S. K. Lindén, P. Sutton, and T. H. Florin, "Mucin dynamics and enteric pathogens," Nature Reviews Microbiology, vol. 9, no. 4, pp. 265-278, 2011.
140. + dendritic cells in the small intestine," Nature, vol. 483, no. 7389, pp. 345-349, 2012.
141. M. A. Kinnebrew and E. G. Pamer, "Innate immune signaling in defense against intestinal microbes," Immunological Reviews, vol. 245, no. 1, pp. 113-131, 2012.
142. N. Miron and V. Cristea, "Enterocytes: active cells in tolerance to food and microbial antigens in the gut," Clinical and Experimental Immunology, vol. 167, no. 3, pp. 405-412, 2012.
143. M. Shan, M. Gentile, J. R. Yeiser et al., "Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals," Science, vol. 342, no. 6157, pp. 447-453, 2013.
144. H. Cheroutre, F. Lambolez, and D. Mucida, "The light and dark sides of intestinal intraepithelial lymphocytes," Nature Reviews Immunology, vol. 11, no. 7, pp. 445-456, 2011.
145. A. M. Mowat, "Anatomical basis of tolerance and immunity to intestinal antigens," Nature Reviews Immunology, vol. 3, no. 4, pp. 331-341, 2003.
146. F. van Wijk and H. Cheroutre, "Mucosal T cell singut homeostasis and inflammation," Expert Review of Clinical Immunology, vol. 6, no. 4, pp. 559-566, 2010.
147. + regulatory T cells in the lamina propria," Immunity, vol. 34, no. 2, pp. 237-246, 2011.
148. M. F. du Pré and J. N. Samsom, "Adaptive T-cell responses regulating oral tolerance to protein antigen," Allergy, vol. 66, no. 4, pp. 478-490, 2011.
149. A. Izcue, J. L. Coombes, and F. Powrie, "Regulatory lymphocytes and intestinal inflammation," Annual Review of Immunology, vol. 27, pp. 313-338, 2009.
150. F. Geissmann, M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley, "Development of monocytes, macrophages, and dendritic cells," Science, vol. 327, no. 5966, pp. 656-661, 2010.
151. R. de Maria, S. Fais, M. Silvestri et al., "Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes," European Journal of Immunology, vol. 23, no. 12, pp. 3104-3108, 1993.
152. R. Testi, D. D'Ambrosio, R. de Maria, and A. Santoni, "The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells," Immunology Today, vol. 15, no. 10, pp. 479-483, 1994.
153. A. S. Llera, F. Viedma, F. Sánchez-Madrid, and J. Tormo, "Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69," Journal of Biological Chemistry, vol. 276, no. 10, pp. 7312-7319, 2001.
154. S. F. Ziegler, S. D. Levin, L. Johnson et al., "The mouse CD69 gene: structure, expression, and mapping to the NK gene complex," Journal of Immunology, vol. 152, no. 3, pp. 1228-1236, 1994.
155. J. Hamann, H. Fiebig, and M. Strauss, "Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain," Journal of Immunology, vol. 150, no. 11, pp. 4920-4927, 1993.
156. E. Alari-Pahissa, L. Notario, E. Lorente et al., "CD69 does not affect the extent of T cell priming," PLoS ONE, vol. 7, no. 10, Article ID e48593, 2012.
157. R. González-Amaro, J. R. Cortés, F. Sánchez-Madrid, and P. Martín, "Is CD69 an effective brake to control inflammatory diseases?" Trends in Molecular Medicine, vol. 19, no. 10, pp. 625-632, 2013.
158. L. Li, D. Qiao, X. Fu, S. Lao, X. Zhang, and C. Wu, "Identification of M. tuberculosis-specific th1 cells expressing CD69 generated in vivo in pleural fluid cells from patients with tuberculous pleurisy," PLoS ONE, vol. 6, no. 8, Article ID e23700, 2011.
159. N. Mori, C. Ishikawa, and M. Senba, "Induction of CD69 expression by cagPAI-positive Helicobacter pylori infection," World Journal of Gastroenterology, vol. 17, no. 32, pp. 3691-3699, 2011.
160. P. Pignatti, L. Perfetti, E. Galdi et al., "Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge," Allergy, vol. 57, no. 5, pp. 411-416, 2002.
161. D. Sancho, A. G. Santis, J. L. Alonso-Lebrero, F. Viedma, R. Tejedor, and F. Sánchez-Madrid, "Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors," Journal of Immunology, vol. 165, no. 7, pp. 3868-3875, 2000.
162. R. Testi, J. H. Phillips, and L. L. Lanier, "T cell activation via Leu-23 (CD69)," The Journal of Immunology, vol. 143, no. 4, pp. 1123-1128, 1989.
163. M. Cebrian, E. Yague, M. Rincon, M. Lopez-Botet, M. O. de Landazuri, and F. Sanchez-Madrid, "Triggering of T cell proliferation through aim, an activation inducer molecule expressed on activated human lymphocytes," Journal of Experimental Medicine, vol. 168, no. 5, pp. 1621-1637, 1988.
164. A. G. Santis, M. R. Campanero, J. L. Alonso et al., "Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway," European Journal of Immunology, vol. 22, no. 5, pp. 1253-1259, 1992.
165. R. de Maria, M. G. Cifone, R. Trotta et al., "Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors," Journal of Experimental Medicine, vol. 180, no. 5, pp. 1999-2004, 1994.
166. I. B. Mcinnes, B. P. Leung, R. D. Sturrock, M. Field, and F. Y. Liew, "Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis," Nature Medicine, vol. 3, no. 2, pp. 189-195, 1997.
167. P. Lauzurica, D. Sancho, M. Torres et al., "Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice," Blood, vol. 95, no. 7, pp. 2312-2320, 2000.
168. P. Martín, M. Gómez, A. Lamana et al., "The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity," Journal of Allergy and Clinical Immunology, vol. 126, no. 2, pp. 355-365.e3, 2010.
169. T. Miki-Hosokawa, A. Hasegawa, C. Iwamura et al., "CD69 controls the pathogenesis of allergic airway inflammation," Journal of Immunology, vol. 183, no. 12, pp. 8203-8215, 2009.
170. K. Murata, M. Inami, A. Hasegawa et al., "CD69-null mice protected from arthritis induced with anti-type II collagen antibodies," International Immunology, vol. 15, no. 8, pp. 987-992, 2003.
171. D. Sancho, M. Gómez, F. Viedma et al., "CD69 downregulates autoimmune reactivity through active transforming growth factor-α production in collagen-induced arthritis," The Journal of Clinical Investigation, vol. 112, no. 6, pp. 872-882, 2003.
172. A. Lamana, D. Sancho, A. Cruz-Adalia et al., "The role of CD69 in acute neutrophil-mediated inflammation," European Journal of Immunology, vol. 36, no. 10, pp. 2632-2638, 2006.
173. A. Cruz-Adalia, L. J. Jiménez-Borreguero, M. Ramírez-Huesca et al., "CD69 limits the severity of cardiomyopathy after autoimmune myocarditis," Circulation, vol. 122, no. 14, pp. 1396-1404, 2010.
174. J. Vega-Ramos, E. Alari-Pahissa, J. D. Valle et al., "CD69 limits early inflammatory diseases associated with immune response to Listeria monocytogenes infection," Immunology and Cell Biology, vol. 88, no. 7, pp. 707-715, 2010.
175. E. Esplugues, D. Sancho, J. Vega-Ramos et al., "Enhanced antitumor immunity in mice deficient in CD69," Journal of Experimental Medicine, vol. 197, no. 9, pp. 1093-1106, 2003.
176. E. Esplugues, J. Vega-Ramos, D. Cartoixa et al., "Induction of tumor NK-cell immunity by anti-CD69 antibody therapy," Blood, vol. 105, no. 11, pp. 4399-4406, 2005.
177. K. Radulovic, C. Manta, V. Rossini et al., "CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential," Journal of Immunology, vol. 188, no. 4, pp. 2001-2013, 2012.
178. K. Radulovic, V. Rossini, C. Manta, K. Holzmann, H. A. Kestler, and J. H. Niess, "The early activation marker CD69 regulates the expression of chemokines and CD4 T cell accumulation in intestine," PLoS ONE, vol. 8, no. 6, Article ID e65413, 2013.
179. A. Hasegawa, C. Iwamura, M. Kitajima et al., "Crucial role for CD69 in the pathogenesis of dextran sulphate sodium-induced colitis," PLoS ONE, vol. 8, no. 6, Article ID e65494, 2013.
180. A. G. Santis, M. López-Cabrera, J. Hamann, M. Strauss, and F. Sánchez-Madrid, "Structure of the gene coding for the human early lymphocyte activation antigen CD69: a C-type lectin receptor evolutionarily related with the gene families of natural killer cell-specific receptors," European Journal of Immunology, vol. 24, no. 7, pp. 1692-1697, 1994.
181. J. M. Bjorndahl, S. Nakamura, T. Hara, L. K. L. Jung, and S. Man Fu, "The 28-kDa/32-kDa activation antigen EA 1. Further characterization and signal requirements for its expression," Journal of Immunology, vol. 141, no. 12, pp. 4094-4100, 1988.
182. F. Gerosa, M. Tommasi, M. Scardoni et al., "Structural analysis of the CD69 early activation directed to different epitopes," Molecular Immunology, vol. 28, no. 1-2, pp. 159-168, 1991.
183. K. Radulovic, The role of CD69 molecule in the mucosal immune system of the intestine [Ph.D. thesis], University of Ulm, 2012, http://vts.uni-ulm.de/docs/2012/8076/vts807611760.pdf.
184. P. Kolenko, T. Skálová, O. Vanek et al., "The high-resolution structure of the extracellular domain of human CD69 using a novel polymer," Acta Crystallographica Section F, vol. 65, pp. 1258-1260, 2009.
185. K. Drickamer, "C-type lectin-like domains," Current Opinion in Structural Biology, vol. 9, no. 5, pp. 585-590, 1999.
186. 2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E," Journal of Biological Chemistry, vol. 288, no. 30, pp. 21667-21677, 2013.
187. A. Cerutti, L. Trentin, R. Zambello et al., "The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity," Journal of Immunology, vol. 157, no. 5, pp. 1854-1862, 1996.
188. R. A. Childs, C. Galustian, A. M. Lawson et al., "Recombinant soluble human CD69 dimer produced in Escherichia coli: reevaluation of saccharide binding," Biochemical and Biophysical Research Communications, vol. 266, no. 1, pp. 19-23, 1999.
189. D. S. Aaronson and C. M. Horvath, "A road map for those who don't know JAK-STAT," Science, vol. 296, no. 5573, pp. 1653-1655, 2002.
190. R. Testi, J. H. Phillips, and L. L. Lanier, "Constitutive expression of A phosphorylated activation antigen (Leu 23) by CD3(bright) human thymocytes," Journal of Immunology, vol. 141, no. 8, pp. 2557-2563, 1988.
191. R. Testi, F. Pulcinelli, L. Frati, P. P. Gazzaniga, and A. Santoni, "CD69 is expressed on platelets and mediates platelet activation and aggregation," Journal of Experimental Medicine, vol. 172, no. 3, pp. 701-707, 1990.
192. P. Sanchez-Mateos, M. Cebrian, A. Acevedo, M. Lopez-Botet, M. O. De Landazuri, and F. Sanchez-Madrid, "Expression of a gp33/27, 000MWactivation inducer molecule (AIM)on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies," Immunology, vol. 68, no. 1, pp. 72-79, 1989.
193. A. Risso, D. Smilovich, M. C. Capra et al., "CD69 in resting and activated T lymphocytes: its association with a GTP binding protein and biochemical requirements for its expression," Journal of Immunology, vol. 146, no. 12, pp. 4105-4114, 1991.
194. L. R. Shiow, D. B. Rosen, N. Brdičková et al., "CD69 acts downstream of interferon-α/β to inhibit S1P 1 and lymphocyte egress from lymphoid organs," Nature, vol. 440, no. 7083, pp. 540-544, 2006.
195. E. Kamphuis, T. Junt, Z. Waibler, R. Forster, and U. Kalinke, "Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia," Blood, vol. 108, no. 10, pp. 3253-3261, 2006.
196. M. Reddy, E. Eirikis, C. Davis, H. M. Davis, and U. Prabhakar, "Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function," Journal of Immunological Methods, vol. 293, no. 1-2, pp. 127-142, 2004.
197. R. Testi, J. H. Phillips, and L. L. Lanier, "Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C," Journal of Immunology, vol. 142, no. 6, pp. 1854-1860, 1989.
198. C. Fiocchi, "Future of IBD pathogenesis: how much work is left to do?" Inflammatory Bowel Diseases, vol. 14, supplement 2, pp. S145-S147, 2008.
199. S. P. Jeong, J.-A. Kang, and S.-G. Park, "Intestinal intraepithelial TCRγδ+ T cells are activated by normal commensal bacteria," The Journal of Microbiology, vol. 50, no. 5, pp. 837-841, 2012.
200. S. Mandala, R. Hajdu, J. Bergstrom et al., "Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists," Science, vol. 296, no. 5566, pp. 346-349, 2002.
201. R. Elgueta, F. E. Sepulveda, F. Vilches et al., "Imprinting of CCR9 on CD4 T cells requires IL-4 signaling on mesenteric lymph node dendritic cells," The Journal of Immunology, vol. 180, no. 10, pp. 6501-6507, 2008.
202. S. I. Hammerschmidt, M. Friedrichsen, J. Boelter et al., "Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice," Journal of Clinical Investigation, vol. 121, no. 8, pp. 3051-3061, 2011.
203. J. R. Mora, "Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids," Inflammatory Bowel Diseases, vol. 14, no. 2, pp. 275-289, 2008.
204. V. Brinkmann, "FTY720: mechanism of action and potential benefit in organ transplantation," Yonsei Medical Journal, vol. 45, no. 6, pp. 991-997, 2004.
205. I. L. Grigorova, S. R. Schwab, T. G. Phan et al., "Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells," Nature Immunology, vol. 10, no. 1, pp. 58-65, 2009.
206. A. D. Luster, R. Alon, and U. H. von Andrian, "Immune cell migration in inflammation: present and future therapeutic targets," Nature Immunology, vol. 6, no. 12, pp. 1182-1190, 2005.
207. M. Matloubian, C.G. Lo, G. Cinamonetal., "Lymphocytee gress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1," Nature, vol. 427, no. 6972, pp. 355-360, 2004.
208. C. Feng, K. J. Woodside, B. A. Vance et al., "A potential role for CD69 in thymocyte emigration," International Immunology, vol. 14, no. 6, pp. 535-544, 2002.
209. T. Nakayama, D. J. Kasprowicz, M. Yamashita et al., "The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression," Journal of Immunology, vol. 168, no. 1, pp. 87-94, 2002.
210. O. Schulz, M. Ugur, M. Friedrichsen et al., "Hypertrophy of infected Peyer's patches arises from global, interferonreceptor, and CD69-independent shutdown of lymphocyte egress," Mucosal Immunology, vol. 7, no. 4, pp. 892-904, 2014.
211. + T cells with a distinct phenotype and migratory pattern," The Journal of Immunology, vol. 190, no. 3, pp. 970-976, 2013.
212. G. F. Gerberick, L. W. Cruse, C. M. Miller, E. E. Sikorski, and G. M. Ridder, "Selective modulation of t cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment," Toxicology and Applied Pharmacology, vol. 146, no. 1, pp. 1-10, 1997.
213. R. W. Dutton, L. M. Bradley, and S. L. Swain, "T cell memory," Annual Review of Immunology, vol. 16, pp. 201-223, 1998.
214. F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, "Two subsets of memory T lymphocytes with distinct homing potentials and effector functions," Nature, vol. 401, no. 6754, pp. 708-712, 1999.
215. F. Sallusto, A. Langenkamp, J. Geginat, and A. Lanzavecchia, "Functional subsets of memory T cells identified by CCR7 expression," Current Topics in Microbiology and Immunology, vol. 251, pp. 167-171, 2000.
216. T. Gebhardt and F. R. Carbone, "Immunology: a helpers' guide to infection," Nature, vol. 462, no. 7272, pp. 418-419, 2009.
217. + T cells are resident in normal skin," The Journal of Immunology, vol. 176, no. 7, pp. 4431-4439, 2006.
218. Y.-T. Lee, J. E. Suarez-Ramirez, T. Wu et al., "Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes," Journal of Virology, vol. 85, no. 9, pp. 4085-4094, 2011.
219. D. L. Turner, K. L. Bickham, J. J. Thome et al., "Lung niches for the generation and maintenance of tissue-resident memory T cells," Mucosal Immunology, vol. 7, no. 3, pp. 501-510, 2014.
220. L. M. Wakim, A. Woodward-Davis, and M. J. Bevan, "Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 42, pp. 17872-17879, 2010.
221. K. Tokoyoda, S. Zehentmeier, A. N. Hegazy et al., "Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow," Immunity, vol. 30, no. 5, pp. 721-730, 2009.
222. D. Masopust, V. Vezys, E.J. Wherry, D.L. Barber, and R. Ahmed, "Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population," The Journal of Immunology, vol. 176, no. 4, pp. 2079-2083, 2006.
223. D. Masopust, D. Choo, V. Vezys et al., "Dynamic T cell migration program provides resident memory within intestinal epithelium," Journal of Experimental Medicine, vol. 207, no. 3, pp. 553-564, 2010.
224. K. A. Casey, K. A. Fraser, J. M. Schenkel et al., "Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues," Journal of Immunology, vol. 188, no. 10, pp. 4866-4875, 2012.
225. L. S. Cauley and L. Lefrançois, "Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells," Mucosal Immunology, vol. 6, no. 1, pp. 14-23, 2013.
226. N. Zhang and M. J. Bevan, "Transforming growth factor-β signaling controls the formation and maintenance of gutresident memory T cells by regulating migration and retention," Immunity, vol. 39, no. 4, pp. 687-696, 2013.
227. K. Shinoda, K. Tokoyoda, A. Hanazawa et al., "Type II membrane protein CD69 regulates the formation of resting T-helper memory," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7409-7414, 2012.
228. A. Hanazawa, M. Löhning, A. Radbruch, and K. Tokoyoda, "CD49b/CD69-dependent generation of resting T helper cell memory," Frontiers in Immunology, vol. 4, article 183, 2013.
229. T. Sathaliyawala, M. Kubota, N. Yudanin et al., "Distribution and compartmentalization of human circulating and tissueresident memory T cell subsets," Immunity, vol. 38, no. 1, pp. 187-197, 2013.
230. D. Haribhai, W. Lin, B. Edwards et al., "A central role for induced regulatory T cells in tolerance induction in experimental colitis," Journal of Immunology, vol. 182, no. 6, pp. 3461-3468, 2009.
231. M. Murai, O. Turovskaya, G. Kim et al., "Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis.," Nature immunology, vol. 10, no. 11, pp. 1178-1184, 2009.
232. + regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-γ," Arthritis research & Therapy, vol. 7, no. 2, pp. R402-R415, 2005.
233. W.-P. Zheng and R. A. Flavell, "The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells," Cell, vol. 89, no. 4, pp. 587-596, 1997.
234. E. Martín-Gayo, E. Sierra-Filardi, A. L. Corbí, and M. L. Toribio, "Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development," Blood, vol. 115, no. 26, pp. 5366-5375, 2010.
235. + T regulatory cells," Journal of Immunology, vol. 178, no. 7, pp. 4022-4026, 2007.
236. L. Gorelik and R. A. Flavell, "Transforming growth factor-β in T-cell biology," Nature Reviews Immunology, vol. 2, no. 1, pp. 46-53, 2002.
237. E. M. Shevach, D. Q. Tran, T. S. Davidson, and J. Andersson, "The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T cell function," European Journal of Immunology, vol. 38, no. 4, pp. 915-917, 2008.
238. + regulatory T cells is mediated by cell surface-bound transforming growth factor β," The Journal of Experimental Medicine, vol. 194, no. 5, pp. 629-644, 2001.
239. M. O. Li, Y. Y. Wan, S. Sanjabi, A.-K. L. Robertson, and R. A. Flavell, "Transforming growth factor-β regulation of immune responses," Annual Review of Immunology, vol. 24, pp. 99-146, 2006.
240. M. Marazuela, M. A. García-López, N. Figueroa-Vega et al., "Regulatory T cells in human autoimmune thyroid disease," The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3639-3646, 2006.
241. + T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance," Journal of Immunology, vol. 161, no. 3, pp. 1267-1273, 1998.
242. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1," The Journal of Immunology, vol. 182, no. 1, pp. 111-120, 2009.
243. R. Gandhi, M. F. Farez, Y. Wang, D. Kozoriz, F. J. Quintana, and H. L. Weiner, "Cutting edge: Human latency-associated peptide+ T cells: a novel regulatory T cell subset," Journal of Immunology, vol. 184, no. 9, pp. 4620-4624, 2010.
244. -regulatory T cells involved in disease progression of human hepatocellular carcinoma?" Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1469-1470, 2011.
245. J. Zhu, A. Feng, J. Sun et al., "Increased CD4+CD69+CD25-T cells in patients with hepatocellular carcinoma are associated with tumor progression," Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1519-1526, 2011.
246. D. Sekar, C. Hahn, B. Brüne, E. Roberts, and A. Weigert, "Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity," European Journal of Immunology, vol. 42, no. 6, pp. 1585-1598, 2012.
247. +T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants," Clinical Transplantation, vol. 26, no. 2, pp. E158-E167, 2012.
248. F. Saldanha-Araujo, R. Haddad, K. C. Farias et al., "Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-κB signalling," Journal of Cellular and Molecular Medicine, vol. 16, no. 6, pp. 1232-1244, 2012.
249. + T cell activation, but augments CD69 expression and TGF-beta1-mediated generation of regulatory T cells at late phase," PLoS ONE, vol. 8, no. 4, Article ID e62300, 2013.
250. R. F. Leal, N. Planell, R. Kajekar et al., "Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy," Gut, 2014.
251. M. Z. Cader and A. Kaser, "Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation," Gut, vol. 62, no. 11, pp. 1653-1664, 2013.
252. R. J. Xavier and D. K. Podolsky, "Unravelling the pathogenesis of inflammatory bowel disease," Nature, vol. 448, no. 7152, pp. 427-434, 2007.
253. I. Koboziev, F. Karlsson, and M. B. Grisham, "Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation," Annals of the New York Academy of Sciences, vol. 1207, supplement 1, pp. E86-E93, 2010.
254. D. V. Ostanin, J. Bao, I. Koboziev et al., "T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade," American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 296, no. 2, pp. G135-G146, 2009.
255. C. Abraham and J. H. Cho, "Inflammatory bowel disease," The New England Journal of Medicine, vol. 361, no. 21, pp. 2066-2078, 2009.
256. W. Strober, I. Fuss, and P. Mannon, "The fundamental basis of inflammatory bowel disease," The Journal of Clinical Investigation, vol. 117, no. 3, pp. 514-521, 2007.
257. G. Bouma and W. Strober, "The immunological and genetic basis of inflammatory bowel disease," Nature Reviews Immunology, vol. 3, no. 7, pp. 521-533, 2003.
258. W. S. Garrett, J. I. Gordon, and L. H. Glimcher, "Homeostasis and inflammation in the intestine," Cell, vol. 140, no. 6, pp. 859-870, 2010.
259. A. Kaser, A. H. Lee, A. Franke et al., "XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease," Cell, vol. 134, no. 5, pp. 743-756, 2008.
260. A. Franke, T. Balschun, T. H. Karlsen et al., "Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility," Nature Genetics, vol. 40, no. 11, pp. 1319-1323, 2008.
261. S. Brand, "Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease," Gut, vol. 58, no. 8, pp. 1152-1167, 2009.
262. D. K. Podolsky, "Inflammatory bowel disease," The New England Journal of Medicine, vol. 347, no. 6, pp. 417-429, 2002.
263. L. E. Targownik and C. N. Bernstein, "Infectious and malignant complications of tnf inhibitor therapy in ibd," American Journal of Gastroenterology, vol. 108, no. 12, pp. 1835-1842, 2013.
264. C. P. Tamboli, D. B. Doman, and A. Patel, "Current and future role of biomarkers in Crohn's disease risk assessment and treatment," Clinical and Experimental Gastroenterology, vol. 4, no. 1, pp. 127-140, 2011.
265. H. Ito, M. Takazoe, Y. Fukuda et al., "A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease," Gastroenterology, vol. 126, no. 4, pp. 989-996, 2004.
266. W. J. Sandborn, B. G. Feagan, P. Rutgeerts et al., "Vedolizumab as induction and maintenance therapy for Crohn's disease," The New England Journal of Medicine, vol. 369, no. 8, pp. 711-721, 2013.
267. C. R. Mackay, "Moving targets: cell migration inhibitors as new anti-inflammatory therapies," Nature Immunology, vol. 9, no. 9, pp. 988-998, 2008.
268. M. Eberhardson, P. Marits, M. Jones et al., "Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis," Clinical Immunology, vol. 149, no. 1, pp. 73-82, 2013.
269. M. C. Fantini, A. Rizzo, D. Fina et al., "Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression," Gastroenterology, vol. 136, no. 4, pp. 1308-1316, 2009.
270. T. Hünig, "The storm has cleared: lessons from the CD28 superagonist TGN1412 trial," Nature Reviews Immunology, vol. 12, no. 5, pp. 317-318, 2012.